Bellerophon Therapeutics — Investor Presentation (January 2021)
32 slides from Bellerophon Therapeutics's investor presentation, Jan 11, 2021
Slide 1: 2021 Company Presentation, January 2021
2021 Company Presentation I Company Presentation I January 2021 Bellerophon Therapeutics
Slide 2: Forward Looking Statements
2021 Company Presentation I 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future fina
Slide 3: Bellerophon Therapeutics (BLPH) Company Profile
2021 Company Presentation I • Focused on developing inhaled nitric oxide (iNO) based therapies for management of serious cardiopulmonary and infectious diseases • Portable, lightweight delivery system (INOpulse®) allows for chronic home use • Simplified regulatory approval pathway via existing nitri
Slide 4: Management Team and Chairman
2021 Company Presentation I Jonathan Peacock Chairman 10 years experience as CFO at Amgen and Novartis Pharma Fabian Tenenbaum Chief Executive Officer 15 years of executive-level experience in finance, BD and operations Wassim Fares, M.D., MSc Chief Medical Officer 20 years experience in clinical re
Slide 5: Development Pipeline
2021 Company Presentation I PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Key Milestones fILD Fibrotic Interstitial Lung Disease at risk of Pulmonary Hypertension Phase 2 Hemodynamic Trial Completed Positive results in Feb 2020 Phase 2 Chronic Trial Complete Positive Cohort 1 results in Jan 2019 Positive
Slide 6: INOpulse Delivery System Overview
2021 Company Presentation I Nitric Oxide Portable pulsatile iNO delivery system Novel drug-device combination therapy with multiple mechanisms of action Well-established vasodilator approved for acute treatment of persistent pulmonary hypertension in hospitals Proprietary algorithm ensures accurate
Slide 7: INOpulse Delivery System: Lightweight, Portable and User Friendly
2021 Company Presentation I 7 INOpulse Delivery System Lightweight, Portable and User Friendly Alarm Cannula Key & ConnectorDrug & Battery Indicators Power Oxygen Sources Easy engagement with drug cartridge Intuitive and simple user interface Tri-lumen cannula allows direct connection with oxygen Li
Slide 8: INOpulse Provides a Unique and Differentiating Mechanism of Action
2021 Company Presentation I 8 INOpulse Provides a Unique and Differentiating Mechanism of Action Baseline Hypoxic pulmonary vasoconstriction prevents oxygen desaturation Systemic Vasodilators Systemic vasodilators can reverse hypoxic vasoconstriction leading to ventilation/perfusion (V/Q) mismatch a
Slide 9: Fibrotic Interstitial Lung Disease (fILD): A Significant Unmet Medical Need
2021 Company Presentation I 9 Fibrotic Interstitial Lung Disease (fILD) A Significant Unmet Medical Need Normal IPF • Fibrotic Interstitial Lung Disease (fILD) is a broad category of diffuse lung diseases characterized by variable amounts of inflammation and fibrosis • Idiopathic Pulmonary Fibrosis
Slide 10: Pulmonary Hypertension associated with fILD Significantly Reduces Survival
2021 Company Presentation I 10 Pulmonary Hypertension (PH) associated with fILD Significantly Reduces Survival Pulmonary Hypertension as Predictor of Survival in IPF • Approximately 40% of IPF patients exhibit symptoms of pulmonary hypertension at rest • Prognosis and survival are significantly wors
Slide 11: fILD Market Opportunity in the US
2021 Company Presentation I Source: LEK report (2018) 11 fILD Market Opportunity in the US 0 500 1,000 1,500 2,000 2,500 3,000 2017 2022E IPF branded drug sales (2017) Millions of USD ~3,000 Estimated Penetration: ~24,000 in US Based on: LTOT penetration of 70-75% Physician adoption rate of 35-60% P
Slide 12: Phase 2: INOpulse Demonstrates Targeted Vasodilation in fILD
2021 Company Presentation I Targeted Vasodilation Ventilation/Vasodilation Matching 12 Phase 2: INOpulse Demonstrates Targeted Vasodilation in fILD Acute Phase Data Showed Immediate Benefit of INOpulse on Vasodilation and Hemodynamics • Significant correlation between ventilation and vasodilation, d
Slide 13: Phase 2: INOpulse Demonstrates Acute Hemodynamic Benefit in fILD
2021 Company Presentation I 13 Phase 2: INOpulse Demonstrates Acute Hemodynamic Benefit in fILD Clinically and statistically meaningful cardiopulmonary improvement on iNO30 w/ cont. benefit on dose escalation Pulmonary hemodynamics measured via right heart catheterization at baseline and following e
Slide 14: Continuous Monitoring of Physical Activity
2021 Company Presentation I Continuous Monitoring of Physical Activity Study participant wears actigraphy monitor on non- dominant arm Monitor continuously measures movement in acceleration units Movement is Categorized into Activity Intensity Levels Activity Intensity Example activities Sedentary (
Slide 15: Phase 2 Results Suggest Clinically Meaningful Benefit in MVPA
2021 Company Presentation I 15 Phase 2 Results Suggest Clinically Meaningful Benefit in MVPA (moderate to vigorous physical activity) • Study participants on INOpulse (iNO30 and iNO45) maintain activity levels while study participants on placebo deteriorate across activity parameters • Study partici
Slide 16: Phase 2 Patient Demographics
2021 Company Presentation I 16 Cohort 1 (n=41) iNO 30 n=23 Placebo n=18 Age – years (mean, SD) 68.6 (6.45) 65.8 (13.73) Male (n, %) 16 (69.6%) 13 (72.2%) Intermediate to High Probability of PH (n, %) 15 (65.2%) 14 (77.8%) Baseline DLCO – % predicted (mean, SD) 30.7 (11.4) 30.4 (10.2) Baseline FVC –
Slide 17: Longitudinal Benefit of iNO in MVPA and Overall Activity
2021 Company Presentation I 17 Analysis based on MMRM model to estimate therapeutic benefit through treatment period based on all available data as planned for pivotal Phase 3 study 20% benefit after 4 months of treatment p=0.02 Overall ActivityMVPA 7% benefit after 4 months of treatment Longitudina
Slide 18: Benefit Observed in MVPA at Month 4 on iNO45
2021 Company Presentation I 18 Study participants on INOpulse maintain activity levels while study participants on placebo deteriorate Study participants on INOpulse demonstrate 7.5 min/day (~10%) benefit over placebo after 2 months of treatment p=0.02 MVPA Month 4MVPA Month 2 Benefit increases to 1
Slide 19: Continued Benefit for Participants on Open Label Extension
2021 Company Presentation I 19 Continued Benefit for Study Participants on Open Label Extension (OLE) Study participants transitioning from placebo to active demonstrate trend reversal from deterioration to maintenance • MVPA = moderate to vigorous physical activity • Change is based on Cohort 1 stu
Slide 20: UCSD Shortness of Breath Questionnaire Indicates Benefit in Dyspnea
2021 Company Presentation I 20 • Placebo corrected improvement of 4 points • Measures shortness of breath while study participants perform daily physical activity Increased score indicative of worsening UCSD SOBQ iNO45: UCSD Shortness of Breath Questionnaire (SOBQ) Indicates Benefit in Dyspnea • Dat
Slide 21: St. George's Respiratory Questionnaire Indicates QOL Benefit
2021 Company Presentation I 21 • Placebo corrected improvement of 6 points • Measures psychological and social impact of the disease • Placebo corrected improvement of 6 points • Measures disturbances to study participants’ daily physical activity • Placebo corrected improvement of 4 points • Measur
Slide 22: Phase 2 Safety Summary
2021 Company Presentation I 22 Phase 2 Safety Summary INOpulse was well-tolerated in Cohort 1 and Cohort 2 Cohort 1 (8 weeks) iNO 30 n=23 Placebo n=18 Study participants with Adverse Events 19 (82.6%) 15 (83.3%) Study participants with Serious Adverse Events 2 (8.7%) 2 (11.1%) Total Serious Adverse
Slide 23: Phase 2 Results Allow Immediate Transition into Pivotal Phase 3 Trial
2021 Company Presentation I PHASE 2 PHASE 3 23 Double-blind placebo-controlled study will assess study participants with fibrotic interstitial lung disease at risk of associated pulmonary hypertension • Phase 2 Complete: Cohorts 1 and 2 suggest improvement in MVPA supported by other activity paramet
Slide 24: An Orphan Unmet Medical Need: PH associated with Sarcoidosis
2021 Company Presentation I An Orphan Unmet Medical Need Pulmonary Hypertension associated with Sarcoidosis (PH-Sarc) 24 Patients with associated PH have significantly reduced survival 1-year survival 3-year survival 5-year survival PH-Sarc 84% 74% 59% Sarc 100% 96% 96% Sarcoidosis is characterized
Slide 25: INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients
2021 Company Presentation I 25 INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients Inhaled nitric oxide has been shown to improve hemodynamics and exercise capacity in PH-Sarc Preston et al., Chest, 2001 Chronic Benefit on Exercise Capacity Acute Hemodynamic Benefit on iNO Paramete
Slide 26: PH-COPD Represents Large Unmet Medical Need
2021 Company Presentation I Andersen KH et al. Prevalence, Predictors and Survival in Pulmonary Hypertension Related to End-stage Chronic Obstructive Pulmonary Disease. Journal of Heart and Lung Transplantation 2012; 31: 373-380. 26 • Typically associated with smoking or exposure to other pollutants
Slide 27: INOpulse Improves Hemodynamics and Exercise Capacity in PH-COPD Patients
2021 Company Presentation I Haijan et al., Int J of COPD, 2016 27 p<0.05* p<0.05* p<0.05* Change in 6MWD sPAP *Statistically significant compared to baseline Study participants completing 4 weeks on iNO 30 demonstrated: • Statistically significant increase in 6MWD at 2 weeks and 4 weeks (+50.7m) • S
Slide 28: INOpulse for the Treatment of COVID-19
2021 Company Presentation I 28 INOpulse for the Treatment of COVID-19 FDA granted emergency expanded access for pulsatile inhaled nitric oxide for treating COVID-19 • 180 patients treated at 18 hospitals across the US under emergency expanded access • Preliminary data demonstrated recovery rate of 7
Slide 29: INOpulse Intellectual Property Protection
2021 Company Presentation I 29 INOpulse Intellectual Property Protection Orphan Drug designation for IPF provides exclusivity for 7 years (US) and up to 10 years (EU) Patent Status Expiration Description Method of NO administration US/EU: Issued Other Territories: Issued/Pending Jan 2027 Covers cons
Slide 30: Financial Summary
2021 Company Presentation I 1. As of September 30, 2020 30 Financial Summary Amount (in millions) Cash and Cash Equivalents $54.0 (1) Restricted Cash $0.4(1) Debt $0(1) Fully Diluted Shares Outstanding 12.2
Slide 31: Investment Highlights Summary
2021 Company Presentation I Established iNO Therapeutic Benefit • Approved for acute treatment of persistent pulmonary hypertension in neonates • Positive results from multiple Phase 2 studies support INOpulse MoA and benefit Advanced Clinical Stage Product INOpulse technology focused on several lar
Slide 32: Investor Contacts
2021 Company Presentation I Investor Contacts Fabian Tenenbaum Chief Executive Officer [email protected] Brian Ritchie LifeSci Advisors [email protected] 212-915-2578
Bellerophon Therapeutics — Investor Presentation (January 2021) on 6ix